EGFR and lung cancer: Tseng et al. reported that patients with EGFR-mutant lung cancer treated with primary tumor resection, in addition to a first-line EGFR-TKI, experienced significantly longer PFS (25.1 months [95% CI: 16.6–33.7 months] vs. 9.4 months [95% CI: 8.4–10.4 months]; adjusted HR [95% CI]: 0.40 [0.30–0.54], p < 0.001) and OS (56.8 months [95% CI: 36.3–77.2 months] vs. 31.8 months [95% CI: 28.2–35.4 months]; adjusted HR [95% CI]: 0.57 [0.39–0.84], p = 0.004) than patients treated with an EGFR-TKI alone [22].